- Home
- YQ vs NRXP Comparison
YQ vs NRXP Comparison
Compare YQ & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YQ | NRXP |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.3M | 54.2M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | YQ | NRXP |
|---|---|---|
| Price | $2.56 | $1.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 2.9K | ★ 600.6K |
| Earning Date | 03-24-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $847.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $1.58 |
| 52 Week High | $6.45 | $3.84 |
Technical Indicators
Market Signals| Indicator | YQ | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 33.83 | 46.90 |
| Support Level | $2.44 | $1.66 |
| Resistance Level | $3.74 | $1.99 |
| Average True Range (ATR) | 0.14 | 0.12 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 15.19 | 27.93 |
Price Performance
Historical ComparisonAbout YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.